The treatment of levodopa-induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy.The purpose of this study was to investigate the efficacy and safety of 274 mg ADS-5102 (amantadine) extended-release capsules (equivalent to 340-mg amantadine HCl) for levodopa-induced dyskinesia in a randomized controlled trial.PD patients with ≥1 hour of troublesome dyskinesia and at least mild functional impact were randomized to placebo or ADS-5102 once daily at bedtime for 13 weeks. The primary efficacy analysis was based on change from baseline to week 12 on the Unified Dyskinesia Rating Scale total score in the modified intent-to-treat population. OFF time was a key secondary measure.At week 12, least-squares mean change in the Unified Dyskinesia Rating Scale was -20.7 (standard error 2.2) for ADS-5102 (n = 37) and -6.3 (standard error 2.1) for placebo (n = 38; treatment difference -14.4, 95

作者：Wolfgang, Oertel；Karla, Eggert；Rajesh, Pahwa；Caroline M, Tanner；Robert A, Hauser；Claudia, Trenkwalder；Reinhard, Ehret；Jean Philippe, Azulay；Stuart, Isaacson；Larissa, Felt；Mary Jean, Stempien

来源：Movement disorders : official journal of the Movement Disorder Society 2017 年